Laura Simon-Szabó

Dr. Laura Simon-Szabó

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ZNZsuzsanna Németh
Zsuzsanna Németh
MPMariann Bukovics Paulinné
Mariann Bukovics Paulinné
LSLiza Dalma Dalma Sümegi
Liza Dalma Dalma Sümegi
GSGábor Sturm
Gábor Sturm
ITIstvan Takacs
Istvan Takacs
LSLaura Simon-Szabó
Laura Simon-Szabó
In addition to conventional treatments, there is growing interest in preventive and complementary therapies. Proper nutrition can prevent the manifestation of several chronic diseases such as obesity, diabetes, cardiovascular disease, and cancer, and can attenuate the severity of these diseases. Edible mushrooms have been used as nutrition and medicine for thousands of years. The spectrum and quantity of their medicinal compounds made them a widely investigated target both in basic research and clinical trials. The most abundant and medically important components are polysaccharides, terpenoids, phenols, and heterocyclic amines, but bioactive proteins, vitamins, including vitamin D, polyunsaturated fatty acids, and essential minerals are also important ingredients with noteworthy health benefits. Mushroom extracts have anti-diabetic, anti-hyperlipidemic, anti-inflammatory, antioxidant, cardioprotective, anti-osteoporotic, and anti-tumor effects and are well tolerated, even by cancer patients. In our previous review we detailed the molecular aspects of the development of type 2 diabetes, discussing the role of physical activity and diet, but we did not detail the role of medicinal mushrooms as part of nutrition. In this review, we aimed to summarize the most important medical mushrooms, along with their natural habitats, growing conditions, and components, that are presumably sufficient for the prevention and treatment of insulin resistance.

Verified
Journal Article
Open access
PDF file
LSLaura Simon-Szabó
Laura Simon-Szabó
BLBeata Lizak
Beata Lizak
GSGábor Sturm
Gábor Sturm
ASAnikó Somogyi
Anikó Somogyi
ITIstvan Takacs
Istvan Takacs
ZNZsuzsanna Németh
Zsuzsanna Németh
The incidence of diabetes, including type 2 diabetes (T2DM), is increasing sharply worldwide. To reverse this, more effective approaches in prevention and treatment are needed. In our review, we sought to summarize normal insulin action and the pathways that primarily influence the development of T2DM. Normal insulin action involves mitogenic and metabolic pathways, as both are important in normal metabolic processes, regeneration, etc. However, through excess energy, both can be hyperactive or attenuated/inactive leading to disturbances in the cellular and systemic regulation with the consequence of cellular stress and systemic inflammation. In this review, we detailed the beneficial molecular changes caused by some important components of nutrition and by exercise, which act in the same molecular targets as the developed drugs, and can revert the damaged pathways. Moreover, these induce entire networks of regulatory mechanisms and proteins to restore unbalanced homeostasis, proving their effectiveness as preventive and complementary therapies. These are the main steps for success in prevention and treatment of developed diseases to rid the body of excess energy, both from stored fats and from overnutrition, while facilitating fat burning with adequate, regular exercise in healthy people, and together with necessary drug treatment as required in patients with insulin resistance and T2DM.

16 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MPMariann Bukovics Paulinné
Mariann Bukovics Paulinné
LSLaura Simon-Szabó
Laura Simon-Szabó
ITIstvan Takacs
Istvan Takacs
ZNZsuzsanna Németh
Zsuzsanna Németh
There is a growing interest in preventive and complementary therapies to support health, increase the effectiveness of conventional medical treatments, and improve quality of life (QoL). This review summarizes the effects of β-glucans, triterpenes and nucleoside analogs of edible and/or medicinal mushrooms with results of clinical trials that investigated these effects in diabetes, breast-, prostate-, lung- and colorectal cancer patients. The results support that these components effectively alleviate symptoms and improve quality of life of these patients. Higher than 3 g of mushrooms, or equivalent extracts, per day are able to diminish metabolic parameters associated with diabetes, i.e., hyperglycemia, hyperlipidemia, and inflammation. The found survival benefit of mushrooms in breast cancer patients was subgroup- or marker-specific. Additionally, their immunomodulatory effects were more complex—different immunological parameters could be either activated or suppressed by different amounts. Data are limited for prostate cancer patients to date, but lentinan intake may increase the survival time of these patients. The survival of lung cancer patients is significantly improved with the use of beta-glucan as complementary therapy. However, its immunomodulatory role was not confirmed. The application of these mushroom components in patients with colorectal cancer may improve QoL. However, survival benefits are inconsistent across different clinical trials of these patients. In summary, although further randomized clinical trials are still required to evaluate optimal dosage and long-term mechanisms of actions in humans, edible and medicinal mushrooms may serve as valuable tools in preventive or in complementary therapies beside the conventional medical treatments of diabetes and cancer.